DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Flixonase Safety in Patients With Allergic Rhinitis (AR)

Information source: GlaxoSmithKline
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Rhinitis, Allergic, Perennial

Intervention: Intermittent, sub-chronic and chronic Flixonase use (Drug); Intermittent, sub-chronic and chronic use of intranasal steroids other than Flixonase (Drug)

Phase: N/A

Status: Completed

Sponsored by: GlaxoSmithKline

Official(s) and/or principal investigator(s):
GSK Clinical Trials, Study Director, Affiliation: GlaxoSmithKline


This is an inception cohort study that analyses data from an administrative medical records database. The two inception cohorts are: 1) patients initiated on intranasal FP and 2) patients initiated on another INS (not FP). The candidates for the inception cohorts did not use any intranasal steroid in the year prior to initiation.

Clinical Details

Official title: Fluticasone Propionate Nasal Spray (Flixonase) Safety in Patients With Allergic Rhinitis Registered in the UK General Practice Research Database

Study design: Observational Model: Cohort, Time Perspective: Retrospective

Primary outcome: Steroid-related outcomes: Cataracts, Glaucoma, Nasal septum perforation, Hypercorticism, Adrenal insufficiency, Fractures (limited to hip, wrist and vertebral as proxies for osteoporosis), Otitis media, Sinusitis, Infectious complications of sinusitis


Minimum age: 4 Years. Maximum age: 85 Years. Gender(s): Both.


Inclusion Criteria:

- Patient records dated between January 1990 - January 2002 were used to develop the

overall study cohort. The cohort was composed of the following patients: 1. All patients with at least one prescription for Flixonase 2. A random sample of patients having at least one prescription for an INS other than Flixonase Exclusion Criteria: Patient-level exclusion

- Patients with less than 180 days of continuous eligibility before index date

- Patients who are under four years of age at index date

- Patients who are older than 85 years of age at index date

Episode-level exclusion

- When patient history was divided into Flixonase or other INS use episodes, patients with

less than 120 days of eligibility after the last prescription in the episode Patients with an event of interest 180 days prior to patients' entry into the cohort or anytime prior to an episode index date were automatically excluded from the analysis of that event. This exclusion criterion was applied to rule out prevalent conditions.

Locations and Contacts

Additional Information

Starting date: January 2008
Last updated: July 30, 2013

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017